ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ENDRA Life Sciences Inc. on December 8, 2022. The report details a corporate action approved by stockholders at a special meeting on November 29, 2022, involving an amendment to the Company's Certificate of Incorporation.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a capital structure adjustment.
Material Changes
- Reverse Stock Split: The Company effected a 1-for-20 reverse stock split of its common stock, effective December 9, 2022, at 12:01 a.m. Eastern time.
- Share Consolidation: Every 20 issued and outstanding shares were automatically combined into one share. No fractional shares were issued; fractional amounts were rounded up to the next whole number.
- Authorized Shares: The total number of authorized shares of Common Stock remains unchanged at 80,000,000.
- Trading Details: The stock began trading on a reverse split-adjusted basis on The Nasdaq Capital Market on December 9, 2022, under the symbol "NDRA" with a new CUSIP number (29273B302).
- Equity Adjustments: Proportionate adjustments were made to the exercise prices and share counts for outstanding stock options and shares reserved under the 2016 Omnibus Incentive Plan.
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard incorporation by reference to the Certificate of Amendment. The primary purpose of the filing is to disclose the execution of the reverse stock split.
Investor Verification Checklist
- Verify the new CUSIP number (29273B302) for the Company's common stock.
- Confirm the adjusted number of shares held in brokerage accounts following the 1-for-20 consolidation.
- Review the impact of the reverse split on the exercise price and share count of any outstanding stock options or warrants.
- Check the Company's definitive proxy statement filed on October 17, 2022, for additional details on the rationale for the split.